Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 759-771

  Kolasinska Malkowska, Katarzyna ^a   Filipiak, Kryzsztof J ^b   Gwizdala, Adrian ^a   Tykarski, Andrzej ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

^c Katedra I Klinika Hipertensjologii   (Poland)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Arterial hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; MONOTHERAPY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; PROTEINURIA; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE MEASUREMENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; MALE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47149110010     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.759     Document Type: Review

References (62)

1. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med. 148, 16-29 (2008).
2. Balcells E, Meng QC, Johnson WH Jr et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol. 273, H1769-H1774 (1997).
3. Ihara M, Urata H, Kinoshita A et al. Increased chymase dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33, 1399-1405 (1999).
4. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101, 844-846 (2000).
5. Cao Z, Kelly DJ, Cox AJ et al. The angiotensin type 2 receptor is expressed in adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 58, 2437-2451 (2000).
6. Sandmann S, Unger T. Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure. Drugs 62(Spec. No. 1), 43-52 (2002).
7. Esteban V, Lorenzo O, Ruiperez M et al. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol. 15, 1514-1529 (2004).
8. Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16, 564-572 (1990).
9. Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J. Am. Soc. Nepbrol. 13, 1773-1787 (2002).
10. Azizi M, Chatellier G, Guyene TT et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92, 825-834 (1995).
11. Azizi M, Guyene TT, Chatellier G et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29, 634-640 (1997).
12. Azizi M, Linhart A, Alexander J et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J. Hypertens. 18, 1139-1147 (2000).
13. Stergiou GS, Skeda I, Baibas NM et al. Additive hypotensive effect of angiotensin concerting enzyme inhibition and angiotensin receptor antagonism in essential Hypertension. J. Cardiovasc. Pharmacol. 35, 937-941 (2000).
14. Ruiz Ortega M, Lorenzo O, Ruiperez M, Koning S, Witting B, Egido J. Angiotensin II activates nuclear transcription factor κB through AT(I) and AT(2) in vascular smooth mucle cells: molecular mechanisms. Circ. Res. 86, 1266-1272 (2000).
15. Guijarro C, Egido J. Transcription factor JCB (NF-κB) and renal disease. Kidney Int. 59, 415-424 (2001).
16. Bonnet F, Cooper ME, Kawachi H et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and Hypertension. Diabetologia 44, 874-877 (2001).
17. Benigni A, Tomasoni S, Gagliardini E et al. Blocking asigiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J. Am. Soc. Nephrol. 12, 941-948 (2001).
18. The GISEN Group. Randomised placeboc-ontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997).
19. Fernandez-Juarez G, Barrio V, Garcia de Vinuesa S, Goicoechea M, Praga M, Luno J. Dual blockade of renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J. Am. Soc. Nephrol. 17, S250-S254 (2006).
20. Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094-1103 (2003).
21. Ruilope L, Aldigier J, Ponticelli C, Oddou-Stock P, Botteri F, Mann J; European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazeprfl in patients with chronic kidney disease. J. Hypertens. 18, 89-95 (2000).
22. Berger E, Bader B, Ebert C, Risler C, Erley C. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme. J. Hypertens. 20, 739-743 (2002).
23. Laverman G, Navis G, Henning R, de Jong P, Zeeuw D. Dual rennin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 62, 1020-1025 (2002).
24. Luño J, Barrio V, Goicoechea M et al. Effects of dual blockade of the rennin-angiotensin system in primary proteinuric nephropathies. Kidney Int. 62(Suppl. 82), S47-S52 (2002).
25. Ferrari P, Marti H, Pfister M, Frey F. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J. Hyperiens. 20, 125-130 (2002).
26. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE): a randomized controlled trial. Lancet 361, 117-124 (2003).
27. Bidani A. Controversy about COOPERATE ABPM trial data. Am. J. Nephrol. 26, 629-632 (2006).
28. Jacobsen P, Andersen S, Rossing K, Hansen B, Parving H. Dual blockade of the rennin-angiotensin system in Type 1 patients with nephropathy. Nephrol. Dial. Transplant. 17, 1019-1024 (2002).
29. Jacobsen P, Andersen S, Jensen B, Parving H. Additive effect ofACE inhibition and angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol. 14, 992-999 (2003).
30. Jacobsen P, Andersen S, Rossing K, Jensen B, Parving H. Dual blockade of the renin-angiotensin system versus maximal recommended (lose of ACE inhibition in diabetic nephropathy. Kidney Int. 63, 1874-1880 (2003).
31. Mogensen C, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of rennin--angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes:the candesartan and hsinopnl microalbuminuria (CALM) study. BMJ 321, 1440-1444 (2000).
32. Rossing K, Christensen P, Jensen B, Parving H. Dual blockade of the remin-angiotensin system in diabetic nephropathy. Diabetes Care 25, 95-100 (2002).
33. Kuntz R, Friedrich C, Wolbers M, Mann J. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008).
34. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362(9386), 759-766 (2003).
35. Cohn JN, Tognoni G; Vilsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blokers valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
36. Jong P, Demers C, McKelvie RS, Liu PP, Angiotensin receptor blockers in heart failure. meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 39, 463-470 (2002).
37. McMurray JJ, Ostergren J, Swedberg K et al. CHARM Investigators and Committees. Effeccs ofcandesartan in patients with chronic heart failure and reduced left-ventricular systolic fimction taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386), 767-771 (2003).
38. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349 (20), 1893-1906 (2003).
39. Swedberg K, Cleland J, Dargie H et al. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment ofchronic heart failure. Eur. Heart J. 26(11), 1115-1140 (2005).
40. Phillips C, Kashani A, Ko D. Adverse effect of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch. Intern. Med. 167(18), 1930-1936 (2007).
41. The Task Force for the Management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J. Hypertens. 25, 1105-1187 (2007).
42. Chobanian A. Bakris G, Black H et al. National Heart, Lung and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
43. Kincaid-Smith P, Fairley KF, Packham D. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol. Dial Transplant. 19, 2272-2274 (2004).
44. Knudsen S, Andersen N, Poulsen S et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ace inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am. J. Hypertens. 21(2), 172-176 (2008).
45. Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J, Tou CK; AMAZE. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J. Clin. Hypertens. 6(9), 485-493 (2004).
46. Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am. J. Hypertens. 14, 665-671 (2001).
47. Forclaz A, Maillard M, Nussberger J et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 41, 31-36 (2003).
48. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45, 880-886 (2005).
49. Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J. Hypertens. 23, 883-889 (2005).
50. Grandi A, Solbiati F, Laurita E et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am. J. Hypertens. 21, 231-237 (2008).
51. Andersen NH, Poulsen PI, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 28, 273-277 (2005).
52. van de Wal RMA, van Veldhuisen DJ, van Gilst VM, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J. 26, 2361-2367 (2005).
53. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol. 47, 726-733 (2006).
54. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114, 838-854 (2006).
55. The Heart Outcomes Prevention Evaluation Study (HOPE) investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
56. Teo K, Yusuf S, Sleight P et al; ON TARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 148, 52-61 (2004).
57. Schrader J, Luders S, Kulszewski A. et al. Morbidity and Mortality after Stroke - Eprosartan Compared With Nitrendypine for Secondary Prevention (MOSES). Stroke 36, 1218-1226 (2005).
58. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033-1041 (2001).
59. Fournier A, Messerli F, Achard J, Fernandez L. Cerebroprorection mediated by angiotensin II: a hypothesis supported by recent randomized trial. J. Am. Coll. Cardiol. 43, 1343-1347 (2004).
60. Dahlof B, Sever P, Poulter N et al. The ASCOT investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering ARM (ASCOT-BPLA); a multicentre randomized controlled trial. Lancet 366, 895-906 (2005).
61. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intevention For Endpoint reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1008 (2002).
62. Julius S, Kjeldsen SE, Weber M et al VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodypine: the VALUE randomized trial. Lancet 363, 2022-2031 (2004).